529 related articles for article (PubMed ID: 25761547)
1. Rescue therapy with intravitreal aflibercept for choroidal neovascularization secondary to choroidal osteoma non-responder to intravitreal bevacizumab and ranibizumab.
Saitta A; Nicolai M; Neri P; Reibaldi M; Giovannini A; Mariotti C
Int Ophthalmol; 2015 Jun; 35(3):441-4. PubMed ID: 25761547
[TBL] [Abstract][Full Text] [Related]
2. Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab.
Maksys S; Richter-Müksch S; Weingessel B; Vécsei-Marlovits PV
Wien Klin Wochenschr; 2017 May; 129(9-10):351-357. PubMed ID: 27550436
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G
Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561
[TBL] [Abstract][Full Text] [Related]
4. Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab (Avastin).
Ahmadieh H; Vafi N
Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1731-3. PubMed ID: 17653753
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks.
Esen E; Sizmaz S; Demircan N
Indian J Ophthalmol; 2015 Jul; 63(7):616-8. PubMed ID: 26458482
[TBL] [Abstract][Full Text] [Related]
6. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
Saito M; Kano M; Itagaki K; Oguchi Y; Sekiryu T
Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
[TBL] [Abstract][Full Text] [Related]
7. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
[TBL] [Abstract][Full Text] [Related]
8. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
9. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
Xu Y; Tan CS
Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
[TBL] [Abstract][Full Text] [Related]
10. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
[TBL] [Abstract][Full Text] [Related]
11. INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION.
Cho HJ; Hwang HJ; Kim HS; Han JI; Lee DW; Kim JW
Retina; 2018 Nov; 38(11):2150-2158. PubMed ID: 28984737
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
Chen YY; Chang PY; Wang JK
Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization.
Wang JK; Huang TL; Chang PY; Chen YT; Chang CW; Chen FT; Hsu YR; Chen YJ
Sci Rep; 2018 Sep; 8(1):14389. PubMed ID: 30258077
[TBL] [Abstract][Full Text] [Related]
14. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept.
Hariri A; Diniz B; Fou LV; Lam LA; Nittala MG; Sadda SR
Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):195-200. PubMed ID: 25707044
[TBL] [Abstract][Full Text] [Related]
15. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
Kaya F
J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
[TBL] [Abstract][Full Text] [Related]
16. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
Ashraf M; Souka AA; ElKayal H
Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
[TBL] [Abstract][Full Text] [Related]
17. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
Fauser S; Muether PS
Br J Ophthalmol; 2016 Nov; 100(11):1494-1498. PubMed ID: 26888975
[TBL] [Abstract][Full Text] [Related]
18. [Intravitreal injection of bevacizumab for CNV secondary to choroidal osteoma and follow-up by Spectral-Domain OCT].
Mercé E; Korobelnik JF; Delyfer MN; Rougier MB
J Fr Ophtalmol; 2012 Sep; 35(7):508-13. PubMed ID: 22695057
[TBL] [Abstract][Full Text] [Related]
19. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.
Homer N; Grewal DS; Mirza RG; Lyon AT; Gill MK
Eye (Lond); 2015 Sep; 29(9):1152-5. PubMed ID: 26021870
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal Administration of Ranibizumab and Bevacizumab for Choroidal Neovascularization Secondary to Ocular Toxocariasis: A Case Report.
Yoon DY; Woo SJ
Ocul Immunol Inflamm; 2018; 26(4):639-641. PubMed ID: 27775459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]